Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
Identifieur interne : 008D05 ( Main/Merge ); précédent : 008D04; suivant : 008D06Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
Auteurs : Pezzoli [Italie] ; E. Martignoni [Italie] ; C. Pacchetti [Italie] ; V. A. Angeleri [Italie] ; P. Lamberti [Italie] ; A. Muratorio [Italie] ; U. Bonuccelli [Italie] ; M. De Mari [Italie] ; N. Foschi [Italie] ; E. Cossutta [Italie] ; F. Nicoletti [Italie] ; F. Giammona [Italie] ; M. Canesi [Italie] ; G. Scarlato [Italie] ; T. Caraceni [Italie] ; E. Moscarelli [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Aged, Bromocriptine, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Infant, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson's disease, Pergolide, Pergolide (adverse effects), Pergolide (therapeutic use), Single-Blind Method, Treatment Outcome.
- MESH :
- chemical , adverse effects : Bromocriptine, Levodopa, Pergolide.
- chemical , therapeutic use : Bromocriptine, Levodopa, Pergolide.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Infant, Male, Middle Aged, Single-Blind Method, Treatment Outcome.
Abstract
We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single‐blind, crossover study. Patients were placed randomly on the sequence bromocriptine‐pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 ± 0.8 mg, and that of bromocriptine was 24.2 ± 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine‐treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short‐term trial.
Url:
DOI: 10.1002/mds.870090409
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002715
- to stream Istex, to step Curation: 002715
- to stream Istex, to step Checkpoint: 003E49
- to stream PubMed, to step Corpus: 004A82
- to stream PubMed, to step Curation: 004A82
- to stream PubMed, to step Checkpoint: 004A85
- to stream Ncbi, to step Merge: 004821
- to stream Ncbi, to step Curation: 004821
- to stream Ncbi, to step Checkpoint: 004821
Links to Exploration step
ISTEX:59255A37FA939BB771C3B14940E03285C7A77CBCLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study</title><author><name sortKey="Pezzoli" sort="Pezzoli" uniqKey="Pezzoli" last="Pezzoli">Pezzoli</name></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E." last="Martignoni">E. Martignoni</name></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C." last="Pacchetti">C. Pacchetti</name></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V. A." last="Angeleri">V. A. Angeleri</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P." last="Lamberti">P. Lamberti</name></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A." last="Muratorio">A. Muratorio</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U." last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M." last="De Mari">M. De Mari</name></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N." last="Foschi">N. Foschi</name></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E." last="Cossutta">E. Cossutta</name></author><author><name sortKey="Nicoletti, F" sort="Nicoletti, F" uniqKey="Nicoletti F" first="F." last="Nicoletti">F. Nicoletti</name></author><author><name sortKey="Giammona, F" sort="Giammona, F" uniqKey="Giammona F" first="F." last="Giammona">F. Giammona</name></author><author><name sortKey="Canesi, M" sort="Canesi, M" uniqKey="Canesi M" first="M." last="Canesi">M. Canesi</name></author><author><name sortKey="Scarlato, G" sort="Scarlato, G" uniqKey="Scarlato G" first="G." last="Scarlato">G. Scarlato</name></author><author><name sortKey="Caraceni, T" sort="Caraceni, T" uniqKey="Caraceni T" first="T." last="Caraceni">T. Caraceni</name></author><author><name sortKey="Moscarelli, E" sort="Moscarelli, E" uniqKey="Moscarelli E" first="E." last="Moscarelli">E. Moscarelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:59255A37FA939BB771C3B14940E03285C7A77CBC</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090409</idno><idno type="url">https://api.istex.fr/document/59255A37FA939BB771C3B14940E03285C7A77CBC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002715</idno><idno type="wicri:Area/Istex/Curation">002715</idno><idno type="wicri:Area/Istex/Checkpoint">003E49</idno><idno type="wicri:doubleKey">0885-3185:1994:Pezzoli:pergolide:compared:with</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:7969210</idno><idno type="wicri:Area/PubMed/Corpus">004A82</idno><idno type="wicri:Area/PubMed/Curation">004A82</idno><idno type="wicri:Area/PubMed/Checkpoint">004A85</idno><idno type="wicri:Area/Ncbi/Merge">004821</idno><idno type="wicri:Area/Ncbi/Curation">004821</idno><idno type="wicri:Area/Ncbi/Checkpoint">004821</idno><idno type="wicri:doubleKey">0885-3185:1994:Pezzoli G:pergolide:compared:with</idno><idno type="wicri:Area/Main/Merge">008D05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study</title><author><name sortKey="Pezzoli" sort="Pezzoli" uniqKey="Pezzoli" last="Pezzoli">Pezzoli</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E." last="Martignoni">E. Martignoni</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute, Universtiy of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C." last="Pacchetti">C. Pacchetti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute, Universtiy of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V. A." last="Angeleri">V. A. Angeleri</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Ancona, Ancona</wicri:regionArea><wicri:noRegion>Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P." last="Lamberti">P. Lamberti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A." last="Muratorio">A. Muratorio</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U." last="Bonuccelli">U. Bonuccelli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M." last="De Mari">M. De Mari</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N." last="Foschi">N. Foschi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Ancona, Ancona</wicri:regionArea><wicri:noRegion>Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E." last="Cossutta">E. Cossutta</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute C. Besta, Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Nicoletti, F" sort="Nicoletti, F" uniqKey="Nicoletti F" first="F." last="Nicoletti">F. Nicoletti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Pharmacology, University of Catania, Catania</wicri:regionArea><wicri:noRegion>Catania</wicri:noRegion></affiliation></author><author><name sortKey="Giammona, F" sort="Giammona, F" uniqKey="Giammona F" first="F." last="Giammona">F. Giammona</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Pharmacology, University of Catania, Catania</wicri:regionArea><wicri:noRegion>Catania</wicri:noRegion></affiliation></author><author><name sortKey="Canesi, M" sort="Canesi, M" uniqKey="Canesi M" first="M." last="Canesi">M. Canesi</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Scarlato, G" sort="Scarlato, G" uniqKey="Scarlato G" first="G." last="Scarlato">G. Scarlato</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Caraceni, T" sort="Caraceni, T" uniqKey="Caraceni T" first="T." last="Caraceni">T. Caraceni</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute C. Besta, Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Moscarelli, E" sort="Moscarelli, E" uniqKey="Moscarelli E" first="E." last="Moscarelli">E. Moscarelli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Eli Lilly Italia, Sesto Fiorentio</wicri:regionArea><wicri:noRegion>Sesto Fiorentio</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="vol">9</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="431">431</biblScope><biblScope unit="page" to="436">436</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">59255A37FA939BB771C3B14940E03285C7A77CBC</idno><idno type="DOI">10.1002/mds.870090409</idno><idno type="ArticleID">MDS870090409</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bromocriptine</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Infant</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Pergolide</term><term>Pergolide (adverse effects)</term><term>Pergolide (therapeutic use)</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single‐blind, crossover study. Patients were placed randomly on the sequence bromocriptine‐pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 ± 0.8 mg, and that of bromocriptine was 24.2 ± 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine‐treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short‐term trial.</div></front></TEI><double doi="10.1002/mds.870090409"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study</title><author><name sortKey="Pezzoli" sort="Pezzoli" uniqKey="Pezzoli" last="Pezzoli">Pezzoli</name></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E." last="Martignoni">E. Martignoni</name></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C." last="Pacchetti">C. Pacchetti</name></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V. A." last="Angeleri">V. A. Angeleri</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P." last="Lamberti">P. Lamberti</name></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A." last="Muratorio">A. Muratorio</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U." last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M." last="De Mari">M. De Mari</name></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N." last="Foschi">N. Foschi</name></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E." last="Cossutta">E. Cossutta</name></author><author><name sortKey="Nicoletti, F" sort="Nicoletti, F" uniqKey="Nicoletti F" first="F." last="Nicoletti">F. Nicoletti</name></author><author><name sortKey="Giammona, F" sort="Giammona, F" uniqKey="Giammona F" first="F." last="Giammona">F. Giammona</name></author><author><name sortKey="Canesi, M" sort="Canesi, M" uniqKey="Canesi M" first="M." last="Canesi">M. Canesi</name></author><author><name sortKey="Scarlato, G" sort="Scarlato, G" uniqKey="Scarlato G" first="G." last="Scarlato">G. Scarlato</name></author><author><name sortKey="Caraceni, T" sort="Caraceni, T" uniqKey="Caraceni T" first="T." last="Caraceni">T. Caraceni</name></author><author><name sortKey="Moscarelli, E" sort="Moscarelli, E" uniqKey="Moscarelli E" first="E." last="Moscarelli">E. Moscarelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:59255A37FA939BB771C3B14940E03285C7A77CBC</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090409</idno><idno type="url">https://api.istex.fr/document/59255A37FA939BB771C3B14940E03285C7A77CBC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002715</idno><idno type="wicri:Area/Istex/Curation">002715</idno><idno type="wicri:Area/Istex/Checkpoint">003E49</idno><idno type="wicri:doubleKey">0885-3185:1994:Pezzoli:pergolide:compared:with</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study</title><author><name sortKey="Pezzoli" sort="Pezzoli" uniqKey="Pezzoli" last="Pezzoli">Pezzoli</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E." last="Martignoni">E. Martignoni</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute, Universtiy of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C." last="Pacchetti">C. Pacchetti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute, Universtiy of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V. A." last="Angeleri">V. A. Angeleri</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Ancona, Ancona</wicri:regionArea><wicri:noRegion>Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P." last="Lamberti">P. Lamberti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A." last="Muratorio">A. Muratorio</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U." last="Bonuccelli">U. Bonuccelli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M." last="De Mari">M. De Mari</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N." last="Foschi">N. Foschi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, University of Ancona, Ancona</wicri:regionArea><wicri:noRegion>Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E." last="Cossutta">E. Cossutta</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute C. Besta, Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Nicoletti, F" sort="Nicoletti, F" uniqKey="Nicoletti F" first="F." last="Nicoletti">F. Nicoletti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Pharmacology, University of Catania, Catania</wicri:regionArea><wicri:noRegion>Catania</wicri:noRegion></affiliation></author><author><name sortKey="Giammona, F" sort="Giammona, F" uniqKey="Giammona F" first="F." last="Giammona">F. Giammona</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Pharmacology, University of Catania, Catania</wicri:regionArea><wicri:noRegion>Catania</wicri:noRegion></affiliation></author><author><name sortKey="Canesi, M" sort="Canesi, M" uniqKey="Canesi M" first="M." last="Canesi">M. Canesi</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Scarlato, G" sort="Scarlato, G" uniqKey="Scarlato G" first="G." last="Scarlato">G. Scarlato</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Caraceni, T" sort="Caraceni, T" uniqKey="Caraceni T" first="T." last="Caraceni">T. Caraceni</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Neurological Institute C. Besta, Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Moscarelli, E" sort="Moscarelli, E" uniqKey="Moscarelli E" first="E." last="Moscarelli">E. Moscarelli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Eli Lilly Italia, Sesto Fiorentio</wicri:regionArea><wicri:noRegion>Sesto Fiorentio</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="vol">9</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="431">431</biblScope><biblScope unit="page" to="436">436</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">59255A37FA939BB771C3B14940E03285C7A77CBC</idno><idno type="DOI">10.1002/mds.870090409</idno><idno type="ArticleID">MDS870090409</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Parkinson's disease</term><term>Pergolide</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single‐blind, crossover study. Patients were placed randomly on the sequence bromocriptine‐pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 ± 0.8 mg, and that of bromocriptine was 24.2 ± 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine‐treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short‐term trial.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.</title><author><name sortKey="Pezzoli, G" sort="Pezzoli, G" uniqKey="Pezzoli G" first="G" last="Pezzoli">G. Pezzoli</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Neurology, University of Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan</wicri:regionArea><wicri:noRegion>University of Milan</wicri:noRegion></affiliation></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E" last="Martignoni">E. Martignoni</name></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C" last="Pacchetti">C. Pacchetti</name></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V A" last="Angeleri">V A Angeleri</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A" last="Muratorio">A. Muratorio</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N" last="Foschi">N. Foschi</name></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E" last="Cossutta">E. Cossutta</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7969210</idno><idno type="pmid">7969210</idno><idno type="doi">10.1002/mds.870090409</idno><idno type="wicri:Area/PubMed/Corpus">004A82</idno><idno type="wicri:Area/PubMed/Curation">004A82</idno><idno type="wicri:Area/PubMed/Checkpoint">004A85</idno><idno type="wicri:Area/Ncbi/Merge">004821</idno><idno type="wicri:Area/Ncbi/Curation">004821</idno><idno type="wicri:Area/Ncbi/Checkpoint">004821</idno><idno type="wicri:doubleKey">0885-3185:1994:Pezzoli G:pergolide:compared:with</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.</title><author><name sortKey="Pezzoli, G" sort="Pezzoli, G" uniqKey="Pezzoli G" first="G" last="Pezzoli">G. Pezzoli</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Neurology, University of Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology, University of Milan</wicri:regionArea><wicri:noRegion>University of Milan</wicri:noRegion></affiliation></author><author><name sortKey="Martignoni, E" sort="Martignoni, E" uniqKey="Martignoni E" first="E" last="Martignoni">E. Martignoni</name></author><author><name sortKey="Pacchetti, C" sort="Pacchetti, C" uniqKey="Pacchetti C" first="C" last="Pacchetti">C. Pacchetti</name></author><author><name sortKey="Angeleri, V A" sort="Angeleri, V A" uniqKey="Angeleri V" first="V A" last="Angeleri">V A Angeleri</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name></author><author><name sortKey="Muratorio, A" sort="Muratorio, A" uniqKey="Muratorio A" first="A" last="Muratorio">A. Muratorio</name></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name></author><author><name sortKey="Foschi, N" sort="Foschi, N" uniqKey="Foschi N" first="N" last="Foschi">N. Foschi</name></author><author><name sortKey="Cossutta, E" sort="Cossutta, E" uniqKey="Cossutta E" first="E" last="Cossutta">E. Cossutta</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Infant</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Pergolide (adverse effects)</term><term>Pergolide (therapeutic use)</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single-blind, crossover study. Patients were placed randomly on the sequence bromocriptine-pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 +/0- 0.8 mg, and that of bromocriptine was 24.2 +/- 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine-treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008D05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 008D05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:59255A37FA939BB771C3B14940E03285C7A77CBC
|texte= Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
}}
| This area was generated with Dilib version V0.6.23. |  |